Compare Ascendis Pharma A/S (ASND) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs KraneShares Hang Seng TECH Index ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while KraneShares Hang Seng TECH Index ETF trades at $13.04. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| ASND | KTEC | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $19.51 |
52-Week Low | $163.32 | $12.00 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KTEC trades at $13.04, down 0.38% with a bullish technical signal from moving averages. The stock shows mixed momentum with a neutral oscillator reading. Support levels cluster around $12-$13 while resistance sits at $13-$14. Key financial ratios including P/E, P/S, and profitability metrics remain unavailable in current data.
The technical setup suggests potential upside if the stock holds above $13 support, though the elevated 6-day RSI indicates near-term overbought conditions. Investment appeal depends on forthcoming financial disclosures to assess valuation and growth prospects against sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
